Ergoteles LLC Prothena Corp Public LTD CO Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $658,025 - $1.07 Million	-13,635 Reduced 50.67%	13,276 $906,000
Q1 2023 May 10, 2023	BUY	$46.97 - $58.27 $534,800 - $663,462	11,386 Added 73.34%	26,911 $1.3 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $610,130 - $761,930	11,722 Added 308.23%	15,525 $935,000
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $95,683 - $230,575	3,803 New	3,803 $231,000
Q1 2022 May 13, 2022	SELL	$30.27 - $49.22 $266,376 - $433,136	-8,800 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $370,568 - $644,688	8,800 New	8,800 $435,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.